Find the clinical detail.
The team needed visibility into BCR-ABL Minor (e1a2) results to identify findings that met the program’s biomarker criteria.
Case study · Acute lymphoblastic leukemia
How a leading biopharmaceutical company used biomarker-specific lab findings, patient segmentation, and weekly alerts to focus engagement with hematologists and oncologists.
Weekly patient averages reflect January–August 2024 and the patient-segmentation criteria used in this program.
Launched in February 2018 and renewed for 2025, the program reflects a sustained commitment to lab-based patient finding and HCP engagement.
The challenge
The client’s commercial team needed to identify patients with specific ALL-related lab findings, distinguish newly diagnosed and relapsed patient groups, and connect those findings to the hematologists and oncologists involved in care.
The team needed visibility into BCR-ABL Minor (e1a2) results to identify findings that met the program’s biomarker criteria.
Distinguishing newly diagnosed and relapsed patient groups would help the team tailor HCP engagement to different clinical contexts.
Field teams needed relevant lab findings linked to HCPs and delivered on a consistent schedule to support engagement planning.
How Prognos helped
Prognos implemented a lab-based alert program using harmonized lab data, biomarker-specific selection, patient segmentation, and HCP mapping.
Prognos identified positive BCR-ABL Minor (e1a2) findings that met the program’s clinical criteria.
Patients were organized into newly diagnosed and relapsed groups using the program’s segmentation criteria.
De-identified patient results were mapped to treating hematologists and oncologists to support commercial follow-up.
HCP alerts were delivered each Wednesday, covering lab activity from the previous Saturday through Friday.
A consistent delivery schedule
Each Wednesday, field teams received alerts based on the previous Saturday–Friday lab activity, creating a consistent schedule for reviewing findings and planning HCP engagement.
Each delivery connected relevant lab findings with patient segments and HCP context, helping teams incorporate those insights into their existing workflows.
Weekly alert delivery
Relevant lab findings + patient segment + HCP context
Program results
From January through August 2024, the program identified an average of 39 newly diagnosed and 5 relapsed patients per week.
January–August 2024
Patients per week · Program averages
Biomarker-specific criteria helped the team identify patients relevant to the program’s commercial objectives.
Distinguishing newly diagnosed and relapsed patient groups gave the team additional context for HCP education and follow-up.
California, Florida, Texas, New Jersey, and North Carolina were among the states with the highest program volumes.
Results reflect this program during January–August 2024. Newly diagnosed and relapsed groups were defined using the program’s segmentation criteria. A biomarker result alone does not establish diagnosis, relapse, or treatment eligibility.
Why the lab detail matters
Diagnostic findings, disease subtypes, and longitudinal testing add clinical detail to the patient journey. Bringing that detail into an HCP alert program helps commercial teams focus on the patient populations and providers relevant to their goals.
Biomarker findings and longitudinal lab results help teams define relevant patient populations with greater clinical detail.
Read the ALL perspective →Connecting clinical criteria, patient segments, and relevant HCPs in a recurring alert program helps teams apply lab insights to engagement planning.
Explore Prognos Oncology →A closer look
Prognos identified BCR-ABL Minor (e1a2) findings, applied the program’s patient-segmentation criteria, and mapped results to treating hematologists and oncologists. The program focused on a specific biomarker-defined population within ALL.
Alerts were delivered weekly on Wednesday, covering the previous Saturday–Friday lab activity.
The program averaged 39 newly diagnosed and 5 relapsed patients identified per week during January–August 2024.
Tell us which biomarkers and patient populations matter to your team. We’ll help define a lab-based approach that supports your HCP engagement goals.
Unlocking the Power of Data to Improve Health.